Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25453253 | 0.83 | CA2 (0.35) | ALDH1A1TP53TDP1MAPTPTGS1 | |
| SCHEMBL14011640 | 0.83 | CA2 (0.35) | ALDH1A1TP53TDP1MAPTPTGS1 | |
| SCHEMBL15592774 | 0.83 | CA2 (0.35) | ALDH1A1TP53TDP1MAPTPTGS1 | |
| SCHEMBL28528975 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TP53TDP1MAPTPTGS1 | |
| SCHEMBL31094181 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TP53TDP1MAPTPTGS1 | |
| SCHEMBL20088239 | 0.76 | TP53 (0.33) | TP53TDP1 | |
| SCHEMBL2089231 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TP53TSHRMAPTPTGS1 | |
| SCHEMBL28474948 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TP53TSHRMAPTPTGS1 | |
| SCHEMBL28474945 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TP53TSHRMAPTPTGS1 | |
| SCHEMBL2089233 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TP53TSHRMAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | ALDH1A1 37/4885TP53 51/4885TSHR 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.